PubRank

Andrea Cipriani

Author PubWeight™ 86.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 8.20
2 Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010 3.72
3 Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006 3.30
4 Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008 3.27
5 Suicide, depression, and antidepressants. BMJ 2005 2.88
6 Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009 2.25
7 Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011 1.89
8 Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013 1.80
9 EMA must improve the quality of its clinical trial reports. BMJ 2011 1.78
10 Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2008 1.70
11 Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015 1.58
12 Implementation of treatment guidelines for specialist mental health care. Cochrane Database Syst Rev 2014 1.56
13 Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005 1.30
14 Selective serotonin reuptake inhibitors. BMJ 2004 1.28
15 Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry 2007 1.20
16 Venlafaxine for major depression. BMJ 2007 1.20
17 "Wish bias" in antidepressant drug trials? J Clin Psychopharmacol 2004 1.17
18 Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008 1.04
19 A fully Bayesian application of the Copas selection model for publication bias extended to network meta-analysis. Stat Med 2012 0.98
20 Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011 0.98
21 Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010 0.95
22 Seven criteria for improving effectiveness trials in psychiatry. Psychol Med 2006 0.94
23 Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014 0.93
24 Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders. Eur J Clin Pharmacol 2012 0.92
25 Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006 0.90
26 Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015 0.89
27 Publication bias in systematic reviews. Arch Gen Psychiatry 2007 0.89
28 Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Stat Med 2014 0.88
29 Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010 0.88
30 Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. Eur J Clin Pharmacol 2007 0.88
31 An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios. Stat Med 2014 0.87
32 Depressive disorders. Clin Evid 2004 0.87
33 Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009 0.86
34 Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2014 0.86
35 [¹²³I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr Res 2012 0.86
36 Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr Epidemiol 2005 0.84
37 Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol 2011 0.84
38 Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. Clin Trials 2013 0.84
39 Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol 2009 0.84
40 Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data. Evid Based Ment Health 2008 0.83
41 International dosage differences in fluoxetine clinical trials. Can J Psychiatry 2005 0.82
42 Validity of the impact factor of journals as a measure of randomized controlled trial quality. J Clin Psychiatry 2006 0.82
43 Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. CNS Drugs 2008 0.82
44 Randomized trials published in Chinese or Western journals: comparative empirical analysis. J Clin Psychopharmacol 2012 0.81
45 Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2013 0.80
46 The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2013 0.80
47 [Randomized trials, systematic reviews, meta-analyses: basic criteria in the world of scientific evidence]. Riv Psichiatr 2012 0.79
48 Risk of suicidal behaviour in adults taking antidepressants. BMJ 2009 0.79
49 Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010 0.79
50 Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. Mini Rev Med Chem 2008 0.79
51 Azapirones versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2014 0.78
52 Assessing risk of bias in randomized controlled trials. Epidemiol Psichiatr Soc 2011 0.78
53 CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) 2006 0.78
54 Depression in adults: drug and physical treatments. BMJ Clin Evid 2007 0.78
55 Agomelatine and the brave old world of narrative-based medicine. Evid Based Ment Health 2012 0.78
56 Implementation of treatment guidelines for specialist mental health care. Schizophr Bull 2014 0.77
57 Time to abandon Evidence Based Medicine? Evid Based Ment Health 2013 0.77
58 Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 2009 0.77
59 Network Meta-analysis for Clinical Practice Guidelines: A Case Study on First-Line Medical Therapies for Primary Open-Angle Glaucoma. Ann Intern Med 2016 0.77
60 Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2015 0.77
61 Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database Syst Rev 2016 0.77
62 Validity of indirect comparisons in meta-analysis. Lancet 2007 0.76
63 Explanatory and pragmatic trials. Epidemiol Psichiatr Soc 2007 0.76
64 Review: maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. Evid Based Ment Health 2009 0.76
65 Treatment choices in women with bipolar disorder seeking pregnancy: a clinical case illustration. Case Rep Psychiatry 2013 0.76
66 Efficacy of antipsychotic drugs for schizophrenia - Authors' reply. Lancet 2013 0.76
67 Review: is aripiprazole as effective as risperidone in people with schizophrenia? Evid Based Ment Health 2010 0.75
68 Cognitive improvements with antipsychotics: real or practice effect? Evid Based Ment Health 2008 0.75
69 Novel melatonin-based treatments for major depression. Lancet 2012 0.75
70 Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. BMC Res Notes 2014 0.75
71 Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects. Evid Based Ment Health 2007 0.75
72 SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. Evid Based Ment Health 2009 0.75
73 Conventional vs. atypical antipsychotic medications. N Engl J Med 2006 0.75
74 Making the best use of available evidence: the case of new generation antidepressants: a response to: are all antidepressants equal? Evid Based Ment Health 2009 0.75
75 Choice of data extraction tools for systematic reviews depends on resources and review complexity. J Clin Epidemiol 2009 0.75
76 Depressive disorder needs an evidence base commensurate with its public health importance. Can J Psychiatry 2007 0.75
77 Outcome reporting bias in clinical trials. Epidemiol Psichiatr Soc 2009 0.75
78 Understanding antipsychotic non-classical prescriptions: a quantitative and qualitative approach. Epidemiol Psichiatr Soc 2008 0.75
79 Nulla dies sine linea. Evid Based Ment Health 2014 0.75
80 Efficacy of antidepressants over placebo is similar in two-armed versus three-armed or more-armed randomized placebo-controlled trials. Int Clin Psychopharmacol 2017 0.75
81 Depressive disorders. Am Fam Physician 2006 0.75
82 Depression in adults. Clin Evid 2006 0.75